A bold claim about future cancer care: early, multi-disease blood tests could reshape how cancer is prevented and treated, and momentum around them is growing in politics and medicine.
Since 2021, excitement has built around multi-cancer early detection tests (MCEDs). The first to draw broad attention was Galleri from GRAIL, which the company says can spot more than 50 cancer types before symptoms appear—at a stage when treatment is likelier to succeed. A second MCED, Cancerguard from Exact Sciences in Madison, Wisconsin, launched in September and is now running a nationwide marketing campaign. Like Galleri, Cancerguard claims it can detect dozens of cancer types in one blood draw, including pancreatic, ovarian, liver, esophageal, lung, and stomach cancers.
These tests are not yet FDA-approved. They currently enter the market as laboratory-developed tests, a category that allows certain accurate diagnoses for conditions with few other options to be offered directly by laboratories. However, they come with a high price tag and are not generally covered by insurance—Cancerguard is priced at $689 per test, limiting access to those who can pay out of pocket.
Despite that, supporters argue MCEDs could dramatically improve cancer prevention by enabling earlier intervention. Healthcare companies, patient advocates, and lawmakers across the political spectrum are pushing to integrate MCEDs into the medical mainstream.
A key legislative effort aims to have Medicare cover MCEDs once the tests receive FDA approval. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (House Bill 842) has gained significant traction, earning 400 co-sponsors and clearing the House Ways and Means committee in a unanimous 43–0 vote in September. Lead sponsor Rep. Terri Sewell, D-Alabama, describes the bipartisan momentum as strong.
Sewell commemorated the measure in honor of her late mother, who died of pancreatic cancer in 2021. Hundreds of cancer advocacy groups visited Capitol Hill to press for policies that improve prevention, early detection, treatment options, and patient support, contributing to the bill’s progress, Sewell notes.
Advocates from the Prevent Cancer Foundation highlight how essential it is to consider Medicare coverage, especially given cost concerns and the risk of false positives that could trigger unnecessary downstream care. The foundation’s CEO, Jody Hoyas, emphasizes the importance of investing in upstream screening even when political and budgetary tensions loom. Although the bill has overwhelming support, it still awaits attachment to a spending vehicle or package, and healthcare negotiations around year-end spending plans add uncertainty.
Hoyas argues that the case for broad screening coverage is deeply relatable: cancer risk rises with age, and currently only five cancer types have routine screening. An estimated 70% of cancers occur without existing screening methods. Early detection generally yields less invasive treatments and better outcomes, which often makes it cheaper in the long run despite upfront costs.
The healthcare industry is pouring resources into MCEDs. Shortly after Cancerguard’s debut, Exact Sciences sold to Abbott Laboratories in a $21 billion deal aiming to dominate the cancer-screening and precision-diagnostics market. Exact Sciences is also known for Cologuard, a noninvasive colorectal cancer test that uses a liquid biopsy approach to detect cancer DNA in the blood.
In development studies, Cancerguard reportedly achieved about 68% sensitivity across six highly lethal cancers and 64% sensitivity overall for a broader set of cancers (excluding breast and prostate). It also identified more than a third of cancers in stage I or II and delivered a high 97.4% specificity, reducing false positives and unnecessary follow-ups.
Modeling suggests that integrating MCEDs with existing screening could cut late-stage diagnoses by about 42% and overall cancer mortality by around 18% over ten years, a potential shift that experts describe as highly compelling.
Dr. Tom Beer, Exact Sciences’ chief medical officer for MCEDs, notes that current screening largely targets a handful of common cancers, leaving hundreds without routine screening. Cancerguard aims to expand coverage to more than 50 cancer types and subtypes, potentially boosting early-detection enthusiasm across the field and accelerating the broader adoption of new screening technologies.
Even so, industry leaders stress that achieving widespread access requires continued clinical evidence and regulatory approval. Beer welcomes the 400 Congressional supporters and hopes for a timely resolution, enabling more patients to access this cutting-edge technology.
Advocates like Hoyas envision a future where cancer is viewed more like a chronic condition—manageable with timely, preventive care—rather than a death sentence. Realizing that future would also drive research and drug development toward early-intervention strategies and broader trial participation, shifting the entire cancer-care landscape.
Read more on related developments and ongoing debates in cancer screening, including shifts in breast cancer trends, lung cancer screening challenges, and evolving long-term outcomes for patients with lung cancer.
Would MCEDs deliver the breakthrough hoped for, or would cost, accuracy, and policy hurdles blunt their impact? Share your perspective on whether Medicare coverage should be a priority and how to balance early detection with the risks and expenses of false positives.
